|1.||Li, Shengjian: 4 articles (01/2008 - 03/2007)|
|2.||Connolly, Peter J: 4 articles (01/2008 - 03/2007)|
|3.||Middleton, Steven A: 4 articles (01/2008 - 03/2007)|
|4.||Liu, Jingchun: 4 articles (01/2008 - 03/2007)|
|5.||Chiu, George: 4 articles (01/2008 - 03/2007)|
|6.||Pulito, Virginia: 3 articles (01/2008 - 07/2007)|
|7.||Yoshimura, Kazuhiro: 1 article (12/2014)|
|8.||Lee, Kang Hyo: 1 article (12/2014)|
|9.||Nozawa, Masahiro: 1 article (12/2014)|
|10.||Kim, Young Ock: 1 article (12/2014)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
07/15/2007 - "Although alpha(1) adrenergic receptor blockers can be very effective for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), their usage is limited by CV-related side-effects that are caused by the subtype non-selective nature of the current drugs. "
01/15/2008 - "Benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) can be effectively treated with alpha(1) adrenergic receptor antagonists. "
11/15/2007 - "Benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) can be effectively treated by alpha(1) adrenergic receptor antagonists, but these drugs also produce side effects that are related to their subtype non-selective nature. "
03/15/2007 - "Subtype-selective alpha-1a and/or alpha-1d adrenergic receptor antagonists may be useful for the treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with fewer adverse effects than non-selective drugs. "
09/22/1998 - "Benign prostatic hyperplasia can be managed pharmacologically with alpha-1 adrenergic receptor antagonists. "
|2.||Prostatic Neoplasms (Prostate Cancer)
02/01/1996 - "The importance is stressed of the drugs blocking the alpha-1 adrenergic receptors in the treatment of mild proliferation of prostatic cancer with additional beneficial mechanisms of action for the organism."
12/01/2014 - "The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract symptoms (LUTS) associated with interstitial (125)I implantation for prostate cancer. "
|4.||Orthostatic Hypotension (Postural Hypotension)
05/01/2005 - "First applications of the alpha(1A) adrenergic receptor model reveal that these in silico tools can be used to guide the chemical optimization towards development candidates with fewer alpha(1A)-mediated side effects (for example, orthostatic hypotension) and, thus, with an improved clinical safety profile."
04/01/2004 - "These data suggest that the etiology of orthostatic hypotension and presyncope after spaceflight includes low alpha(1)-adrenergic receptor responsiveness before flight and a remodeling of the central nervous system during spaceflight such that sympathetic responses to baroreceptor input become impaired."
09/01/1988 - "The role of central alpha-1 adrenergic receptors in cataplexy was investigated in genetically narcoleptic Doberman pinschers. "
06/01/1990 - "Recent experiments have demonstrated that pharmacological activation of central noradrenergic systems by monoaminergic stimulators or uptake blockers or through the stimulation of alpha-1 adrenergic receptors improved cataplexy, a major symptom of narcolepsy. "
09/01/1988 - "Treatment of narcoleptic dogs with 25-600 micrograms/kg prazosin, a selective alpha-1 adrenergic receptor blocker, exacerbated cataplexy, whereas treatment with the alpha-1 agonist, methoxamine, ameliorated it. "
|2.||Radio-Opaque acrylic resin (Boston Post)
|9.||alpha-1 Adrenergic Receptors (alpha 1 Adrenergic Receptor)
|2.||Surgical Instruments (Clip)